Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study

Raimondi, Alessandra; Corallo, Salvatore; Lonardi, Sara; Antoniotti, Carlotta; Rimassa, Lorenza; Amatu, Alessio; Tampellini, Marco; Racca, Patrizia; Murialdo, Roberto; Clavarezza, Matteo; Zaniboni, Alberto; Toscano, Giuseppe; Tomasello, Gianluca; Petrelli, Fausto; Antonuzzo, Lorenzo; Giordano, Monica; Cinieri, Saverio; Longarini, Raffaella; Niger, Monica; Antista, Maria; Ambrosini, Margherita; Pagani, Filippo; Prisciandaro, Michele; Randon, Giovanni; de Braud, Filippo; Di Bartolomeo, Maria; Pietrantonio, Filippo; Morano, Federica

doi:10.1007/s00520-020-05972-2

The combination of anti-EGFRs and doublet chemotherapy is considered the optimal upfront option for patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC). The prophylactic or reactive treatment with tetracyclines for EGFR inhibitor-induced skin toxicity is currently clinical practice, though non-conclusive results are available.

Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study / Raimondi, Alessandra; Corallo, Salvatore; Lonardi, Sara; Antoniotti, Carlotta; Rimassa, Lorenza; Amatu, Alessio; Tampellini, Marco; Racca, Patrizia; Murialdo, Roberto; Clavarezza, Matteo; Zaniboni, Alberto; Toscano, Giuseppe; Tomasello, Gianluca; Petrelli, Fausto; Antonuzzo, Lorenzo; Giordano, Monica; Cinieri, Saverio; Longarini, Raffaella; Niger, Monica; Antista, Maria; Ambrosini, Margherita; Pagani, Filippo; Prisciandaro, Michele; Randon, Giovanni; de Braud, Filippo; Di Bartolomeo, Maria; Pietrantonio, Filippo; Morano, Federica. - In: SUPPORTIVE CARE IN CANCER. - ISSN 1433-7339. - STAMPA. - 29:(2021), pp. 3971-3980. [10.1007/s00520-020-05972-2]